A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
Patients received oral AC220 daily for 14 days to study the side effects, tolerability and
best dose for treating relapsed or refractory acute myeloid leukemia, regardless of FLT3
status.